Abstract

Aim: The 14-3-3η (eta) protein has been associated with the severity of the disease and joint destruction in patients with rheumatoid arthritis (RA). It has also been shown to be likely to be effective in inflammatory events. We aimed to investigate whether eta levels could be a potential biomarker in the diagnosis of ankylosing spondylitis (AS) and in the determination of disease activity in patients with AS.

Methods: This study included 51 patients diagnosed with AS and 49 healthy controls aged 20-65 years. The routine hemogram, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were measured and the neutrophil/lymphocyte ratio (NLR) was calculated in the patients. The serum eta levels were also measured in the patient and healthy control groups. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were used to assess disease activity. Sacroiliac joint radiographs of the patients were evaluated and the sacroiliitis was graded.

Results: There was no statistically significant correlation between the degree of sacroiliitis, disease activity indices, and eta levels. There was no statistically significant correlation between eta levels and hematological parameters except for CRP. There was a negative, weak, and statistically significant relationship between the patients’ eta levels and CRP (r=-0.277; p=0.049). We could not find any correlation between the degree of sacroiliitis, disease activity indexes, and serum eta levels in AS patients.

Conclusion: Serum eta levels are not a good biomarker for detecting disease activity in patients with ankylosing spondylitis. The 14-3-3η protein may play a more active role in rheumatic diseases where peripheral joint involvement is prominent.

Keywords: 14-3-3 proteins, ankylosing spondylitis, biomarkers, mediators of inflammation

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Atalar E, Kor A, Fırat Oğuz E, Konak HE, Orhan K, Maraş Y, et al. Serum 14-3-3 ETA levels in ankylosing spondylitis with pure axial involvement: Could it be a potential biomarker to assess disease activity?. Northwestern Med J. 2023;3(2):115-21. https://doi.org/10.54307/NWMJ.2023.35119

References

  1. Cunha RN, Vieira-Sousa E, Khmelinskii N, et al. Sex differences in axial spondyloarthritis: data from a Portuguese spondyloarthritis cohort. ARP Rheumatol. 2022; 1(1): 42-8.
  2. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018; 30(2): 137-43. https://doi.org/10.1097/BOR.0000000000000475
  3. Braun J, Sieper J. Ankylosing spondylitis. The Lancet. 2007; 369(9570): 1379-90. https://doi.org/10.1016/s0140-6736(07)60635-7
  4. Durmaz Y, İlhanlı İ. Comparison of ankylosing spondylitis patients with and without fibromyalgia syndrome according to the disease activation scores and response to treatment. Turk J Phys Med Rehabil. 2021; 67(4): 509-17. https://doi.org/10.5606/tftrd.2021.7796
  5. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008; 205(2): 331-7. https://doi.org/10.1084/jem.20070906
  6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21: 2286-91.
  7. Kilani RT, Maksymowych WP, Aitken A, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007; 34: 1650-7.
  8. van Heusden GPH. 14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life. 2005; 57(9): 623-9. https://doi.org/10.1080/15216540500252666
  9. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol. 2006; 16(3): 162-72. https://doi.org/10.1016/j.semcancer.2006.03.005
  10. Reyhan I, Zhukov OS, Lagier RJ, et al. Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021; 19(1): 14. https://doi.org/10.1186/s12969-021-00502-8
  11. Johnson C, Crowther S, Stafford MJ, Campbell DG, Toth R, MacKintosh C. Bioinformatic and experimental survey of 14-3-3-binding sites. Biochem J. 2010; 427(1): 69-78. https://doi.org/10.1042/BJ20091834
  12. van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016; 18: 76. https://doi.org/10.1186/s13075-016-0975-4
  13. Maksymowych WP, van der Heijde D, Allaart CF, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014; 16(2): R99. https://doi.org/10.1186/ar4547
  14. Galil SMA, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. 2016; 19(4): 377-84. https://doi.org/10.1111/1756-185X.12434
  15. Hammam N, Gamal NM, Elzohri MH, et al. Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren’s syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis. Clin Rheumatol. 2020; 39(9): 2603-10. https://doi.org/10.1007/s10067-020-05033-3
  16. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999; 26: 980-4.
  17. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007; 74(3): 249-53. https://doi.org/10.1016/j.jbspin.2006.07.005
  18. Zochling J, Braun J. Assessment of ankylosing spondylitis. Clin Exp Rheumatol. 2005; 23(5 Suppl 39): S133-41.
  19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4): 361-8. https://doi.org/10.1002/art.1780270401
  20. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68(12): 1811-8. https://doi.org/10.1136/ard.2008.100826
  21. Gong X, Xu S-Q, Wu Y, et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017; 36(11): 2581-7. https://doi.org/10.1007/s10067-017-3807-2
  22. Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014; 41(11): 2104-13. https://doi.org/10.3899/jrheum.131446
  23. Alashkar DS, Elkhouly RM, Abd Elnaby AY, Nada DW. Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment. Autoimmune Dis. 2022; 2022: 1497748. https://doi.org/10.1155/2022/1497748
  24. Hussin DAAH, Shaat RM, Metwally SS, Awad M. The significance of serum 14-3-3η level in rheumatoid arthritis patients. Clin Rheumatol. 2021; 40(6): 2193-202. https://doi.org/10.1007/s10067-020-05524-3
  25. Guan S-Z, Yang Y-Q, Bai X, et al. Serum 14-3-3η Could Improve the Diagnostic Rate of Rheumatoid Arthritis and Correlates to Disease Activity. Ann Clin Lab Sci. 2019; 49: 57-62.
  26. Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol. 2012; 26(1): 135-45. https://doi.org/10.1016/j.berh.2012.01.002
  27. Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken). 2013; 65(8): 1299-306. https://doi.org/10.1002/acr.21994
  28. Shim MR. Efficacy of TNF inhibitors in advanced ankylosing spondylitis with total spinal fusion: case report and review of literature. Open Access Rheumatol. 2019; 11: 173-7. https://doi.org/10.2147/OARRR.S212456
  29. Maksymowych W, Wichuk S, Murphy M, Marotta A. THU0105 Auto-Antibodies to A Specific 14-3-3Eta Epitope is A Marker of Ankylosing Spondylitis, is Associated with SIJ Inflammation and Predicts Radiographic Progression. Ann Rheum Dis. 2014; 73(Suppl 2): 213.2-214. https://doi.org/10.1136/annrheumdis-2014-eular.6038
  30. Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015; 17: 280. https://doi.org/10.1186/s13075-015-0799-7